Elevated pre-treatment CRP levels have been observed to correlate with tumor aggressiveness, poor treatment response, and unfavorable outcomes in breast cancer patients (Allin et al., 2011; Asegaonkar et al., 2015). The gene discussed is CRP; the disease is neoplasm.